When comparing some of the frequent AML mutations, no significant differences were observed in FLT3-ITD, NPM1, CEBPA, DNMT3A, IDH1, IDH2, WT1, TET2, KIT, PTPN11, and PHF6 between two groups, but there were obvious distinctions between those two groups as higher level of GAS6-mRNA brought higher RUNX1 mutations (P=0.003), MLL-PTD mutations (P=0.042), TP53 mutations (P=0.042), and lower NRAS/KRAS mutations (P=0.042). This evidence concerns the gene TP53 and acute myeloid leukemia.